Trials / Completed
CompletedNCT00395018
Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical research study is to learn if the study drug entecavir will prevent the recurrence of hepatitis B virus (HBV) in participants who receive an orthotopic liver transplant (OLT) due to HBV infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | entecavir | Tablets, Oral, 1 mg, once daily, up to 72 weeks |
Timeline
- Start date
- 2007-04-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2006-11-02
- Last updated
- 2012-05-31
- Results posted
- 2012-05-31
Locations
32 sites across 9 countries: United States, Argentina, Australia, Brazil, France, Italy, South Korea, Spain, Taiwan
Source: ClinicalTrials.gov record NCT00395018. Inclusion in this directory is not an endorsement.